NewsRx

Search our medical news database

Drug Development

Isis Pharmaceuticals Touts New Drug Therapies

Published in Gene Therapy Weekly, February 24th, 1997

Fomivirsen (ISIS 2922) (Isis Pharmaceuticals, Carlsbad, California) continues to demonstrate an attractive safety profile and rapid and long-term control of CMV retinitis in AIDS patients.

Daniel Kisner, M.D., Isis, presented data on the drug at the International Business Communications Meeting on Antisense Therapeutics, held in San Diego, California. Fomivirsen also is effective in AIDS patients who have failed newer CMV retinitis agents such as Vitrasert and Vistide, as well as standard agents.

Isis expects to complete Phase III of fomivirsen trials later in 1997.

Kisner also discussed the positive efficacy results from the...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook